Nasdaq · CIK 0001787740
VBIO Valion Bio, Inc.
Insider trading from SEC Form 4. Last filing 19 d ago.
Valion Bio, Inc. (VBIO) has 25 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 24, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at VBIO. The newest: Sheryle Bolton (director) bought $10k of stock on Apr 15, 2026, filed Apr 20, 2026, scored 23 (weak).
Last 90 days
Signals
Open-market buys and sells at Valion Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Sheryle Bolton director buy | $10k 10,000 shares | - | - |
Transactions
Every row filed, 34 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Lisa G Wolf COO & CFO | MOption exercise Common Stock | +4 | - | - | 29 | 19 d ago |
| Sep 22, 2026 | Dean Zikria Interim CEO | AGrant or award Restricted Stock Unitsderivative | +50,000 | $0.00 | $0 | 50,000 | 19 d ago |
| Sep 18, 2026 | Lisa G Wolf COO & CFO | FTax withholding Common Stock | -2 | $2.12 | $4 | 27 | 19 d ago |
| Sep 18, 2026 | Lisa G Wolf COO & CFO | MOption exercise Restricted Stock Unitsderivative | -4 | $0.00 | $0 | 19 | 19 d ago |
| May 18, 2026 | Michael K Handley Chief Executive Officer | MOption exercise Common Stock | +2,206 | - | - | 11,030 | May 20, 2026 |
| May 18, 2026 | Michael K Handley Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -2,206 | $0.00 | $0 | 24,265 | May 20, 2026 |
| Apr 15, 2026 | Sheryle Bolton director | POpen-market purchase Common Stock | +10,000 | $1.04 | $10k | 10,000 | Apr 20, 2026 |
| Mar 18, 2026 | Lisa G Wolf Chief Financial Officer | MOption exercise Common Stock | +92 | - | - | 526 | Mar 19, 2026 |
| Mar 18, 2026 | Lisa G Wolf Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -92 | $0.00 | $0 | 643 | Mar 19, 2026 |
| Feb 18, 2026 | Michael K Handley Chief Operating Officer | MOption exercise Common Stock | +8,824 | - | - | 8,824 | Feb 20, 2026 |
| Feb 18, 2026 | Michael K Handley Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,824 | $0.00 | $0 | 26,471 | Feb 20, 2026 |
| Dec 18, 2025 | Jennifer Ernst Chief Executive Officer | MOption exercise Common Stock | +14,706 | - | - | 37,953 | Dec 22, 2025 |
| Dec 18, 2025 | Lisa G Wolf Chief Financial Officer | MOption exercise Common Stock | +736 | - | - | 736 | Dec 22, 2025 |
| Dec 18, 2025 | Jennifer Ernst Chief Executive Officer | FTax withholding Common Stock | -5,262 | $1.87 | $9,840 | 32,691 | Dec 22, 2025 |
| Dec 18, 2025 | Lisa G Wolf Chief Financial Officer | FTax withholding Common Stock | -302 | $1.87 | $565 | 434 | Dec 22, 2025 |
| Dec 18, 2025 | Jennifer Ernst Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -14,706 | $0.00 | $0 | 14,706 | Dec 22, 2025 |
| Dec 18, 2025 | Lisa G Wolf Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -736 | $0.00 | $0 | 735 | Dec 22, 2025 |
| Sep 22, 2025 | Jennifer Ernst Chief Executive Officer | AGrant or award Common Stock | +22,541 | $0.00 | $0 | 23,247 | Sep 24, 2025 |
| Aug 6, 2025 | Jennifer Ernst Chief Executive Officer | AGrant or award Employee Stock Option (Right to Purchase)derivative | +85,000 | $0.00 | $0 | 85,000 | Aug 22, 2025 |
| Aug 6, 2025 | Michael K Handley Chief Operating Officer | AGrant or award Employee Stock Option (Right to Purchase)derivative | +45,000 | $0.00 | $0 | 45,000 | Aug 22, 2025 |
| Aug 6, 2025 | Lisa G Wolf Chief Financial Officer | AGrant or award Employee Stock Option (Right to Purchase)derivative | +80,000 | $0.00 | $0 | 80,000 | Aug 22, 2025 |
| Aug 6, 2025 | Sheryle Bolton director | AGrant or award Stock Option (Right to Purchase)derivative | +12,500 | $0.00 | $0 | 12,500 | Aug 8, 2025 |
| Aug 6, 2025 | Jennifer Ernst Chief Executive Officer | AGrant or award Employee Stock Option (Right to Purchase)derivative | +85,000 | $0.00 | $0 | 85,000 | Aug 8, 2025 |
| Aug 6, 2025 | Michael K Handley Chief Operating Officer | AGrant or award Employee Stock Option (Right to Purchase)derivative | +45,000 | $0.00 | $0 | 45,000 | Aug 8, 2025 |
| Aug 6, 2025 | Christina Rizopoulos Valauri director | AGrant or award Stock Option (Right to Purchase)derivative | +7,500 | $0.00 | $0 | 7,500 | Aug 8, 2025 |
| Aug 6, 2025 | Lisa G Wolf Chief Financial Officer | AGrant or award Employee Stock Option (Right to Purchase)derivative | +80,000 | $0.00 | $0 | 80,000 | Aug 8, 2025 |
| Aug 6, 2025 | Dean Zikria Interim CEO | AGrant or award Stock Option (Right to Purchase)derivative | +7,500 | $0.00 | $0 | 7,500 | Aug 8, 2025 |
| Feb 21, 2025 | Michael K Handley Chief Operating Officer | AGrant or award Restricted Stock Unitsderivative | +600,000 | $0.00 | $0 | 600,000 | Feb 24, 2025 |
| Dec 18, 2024 | Sheryle Bolton director | AGrant or award Stock Option (Right to Purchase)derivative | +15,000 | $0.00 | $0 | 15,000 | Dec 20, 2024 |
| Dec 18, 2024 | Jennifer Ernst Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +500,000 | $0.00 | $0 | 500,000 | Dec 20, 2024 |
| Dec 18, 2024 | Blake Gurfein Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +225,000 | $0.00 | $0 | 225,000 | Dec 20, 2024 |
| Dec 18, 2024 | Christina Rizopoulos Valauri director | AGrant or award Stock Option (Right to Purchase)derivative | +12,000 | $0.00 | $0 | 12,000 | Dec 20, 2024 |
| Dec 18, 2024 | Lisa G Wolf Interim CFO | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Dec 20, 2024 |
| Dec 18, 2024 | Dean Zikria Interim CEO | AGrant or award Stock Option (Right to Purchase)derivative | +12,000 | $0.00 | $0 | 12,000 | Dec 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sheryle Boltondirector
- Jennifer ErnstChief Executive Officer
- Blake GurfeinChief Scientific Officer
- Michael K HandleyChief Executive Officer
- Christina Rizopoulos Valauridirector
- Lisa G WolfChief Financial Officer
- Dean ZikriaInterim CEO
Questions about VBIO
Answered from the filings on this page, as of the latest one.
Are insiders buying VBIO?
No. In the last 90 days no insider at Valion Bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade VBIO on the open market?
Sheryle Bolton (director) bought $10k of VBIO on Apr 15, 2026 and filed the Form 4 on Apr 20, 2026. InsiderTell scored 23 (weak).
How many insiders file Form 4 at Valion Bio, Inc.?
7 people have filed a Form 4 at Valion Bio, Inc., among them Sheryle Bolton (director), Jennifer Ernst (Chief Executive Officer), Blake Gurfein (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.